Viewing nowPregabalin Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Medica Korea Co., Ltd.

MFDS item code 201109310 · Approved 2011.10.31 · Insurance code 646003650
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy
This medication is used to treat peripheral and central neuropathic pain in adults and is used as an adjunct for partial seizures in patients with epilepsy. It also helps alleviate symptoms of fibromyalgia. It is effective in improving significant neuropathic and musculoskeletal pain and reducing the frequency of partial seizures. This drug is widely used for symptom relief of various neurological disorders.
This medication is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: The starting dose of this medication may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: The starting dose of this medication may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: The starting dose of this medication may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg to 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, when discontinuing this medication, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with Hepatic Impairment No dose adjustment is required in patients with hepatic impairment. 8. Elderly Patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This drug may increase the risk of suicidal thoughts or behaviors, so if any abnormal changes in mood or behavior occur during treatment, healthcare providers must be informed immediately. This drug should not be administered to patients with an allergy to any of its components or those having specific genetic issues such as lactose intolerance. Diabetic patients should be cautious about blood sugar control as this drug may cause weight gain, and if any allergic reactions such as angioedema occur, use should be stopped immediately. Elderly patients may experience exacerbated dizziness and drowsiness while taking this drug, increasing the risk of falls, and should consult healthcare providers if experiencing visual changes such as blurred vision. Abrupt discontinuation of this drug may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it is advisable to taper off gradually after consultation with a healthcare provider. Patients with a history of substance abuse may have an increased risk of misuse of this drug and should be monitored closely during administration. Patients with impaired kidney function may need dose adjustments of this drug. Patients with heart disease should be cautious as cardiovascular abnormalities such as congestive heart failure may occur while taking this drug. The risk of central nervous system depression increases when taken with opioid analgesics, so caution is advised during co-administration. Pregnant women should avoid taking this drug in early pregnancy due to the risk of fetal malformations, and sexually active women should use effective contraception. Breastfeeding women should consult healthcare providers as this drug can be transferred via breast milk and may need to discontinue feeding. This drug can cause dizziness and drowsiness; therefore, driving or operating hazardous machinery should be avoided after ingestion. In case of overdose, symptoms such as mental confusion, drowsiness, and seizures may occur, necessitating immediate emergency treatment. Store this drug out of reach of children in a safe place, and do not transfer it to another container. If severe allergic reactions such as skin rash, fever, or breathing difficulties occur during the use of this drug, use should be stopped immediately, and healthcare providers should be contacted.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container to protect it from air and moisture and kept at room temperature between 15 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness.
An opaque capsule with white or slightly yellow powder inside, both top and bottom are white.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Medica Korea Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.